FDA cleared histotripsy in late 2023. As of February 2026, HistoSonics' Edison system has treated thousands of patients (nearly 3,000 reported in recent updates) at over 50 leading US centers (e.g., Allina Health/Abbott Northwestern, Johns Hopkins affiliates, Jersey Shore UMC, Saint Francis, Lehigh Valley, Renown Health, UM Health-West, plus expansions in UAE, Hong Kong, and early Europe/UK sites).
Real-world results: Multicenter data show 94-96% local tumor control at 30-90 days post-treatment (many cases 100% when properly targeted), with ~90% at 1 year in pivotal trial follow-ups. Complications are low/rare (mostly minor or disease-related; serious ones <7% in early analyses, often not device-specific). Outpatient sessions, quick recovery—patients often resume normal life fast.
Patient stories: "The contrast vs. surgery was huge—I was with family, not stuck in bed." "No pain, back to dinner next day." "A godsend for tumors nothing else could touch." "Miracle treatment."
Immune boost bonus: Liquefied debris may help the body recognize and fight remaining cancer cells.
From breakthrough to real-world rollout in under 3 years—this is changing liver cancer care now, with kidney/pancreas trials advancing rapidly.
Non-invasive tumor destruction via sound is here.
What cutting-edge medical advance gives you the most hope heading into the rest of 2026?
NO DATA FOUND. INITIATE FIRST COMMENT SEQUENCE.